Clinical trials: Tumors Metastatic to Brain
Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma
Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
The purpose of this research study is to test an experimental treatment method for recurrent or progressive brain tumors in children aged from 0-22 years.
- Conditions
- Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes
- Trial name
- NCT02684071
- Testing
- Intra thecal methotrexate, topotecan, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Brain Metastases
IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases
This is a Phase I Study evaluating the safety and feasibility of IL-8 receptor-modified patient-derived activated CD70 CAR T cells in adult patients with brain metastases from primary cancer, with either newly diagnosed lesions…
- Trial name
- IMPACT MET (NCT07569263)
- Testing
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells, CD70 IHC assay
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
Solid Tumor Malignancies, Brain Metastasases
Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study
This is a prospective, single-centre feasibility study of CSF ctDNA conducted at the Sunnybrook Odette Cancer Centre (SOCC), Toronto, Canada, including multiple solid tumor, stratified into cohorts according to CNS disease…
- Conditions
- Solid Tumor Malignancies, Brain Metastasases, Leptomeningeal Disease (LMD), Central Nervous System
- Trial name
- ECLIPSE (NCT07476781)
- Testing
- One time CSF and blood sample
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic Solid Tumor, Brain Metastases
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.
- Trial name
- NCT05673928
- Testing
- Trastuzumab emtansine, Tucatinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Metastases, Adult
Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery
Brain metastases (BM) represents a devastating clinical reality, carrying an estimated survival time of less than one year. Number of reasons, including complicated tumor biology and difficulties in modeling metastatic cancer in…
- Trial name
- NCT04785521
- Testing
- Stereotactic radiosurgery, Blood samples
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS San Raffaele
Metastasis, Breast Cancer
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated…
- Trial name
- ATTAIN (NCT02915744)
- Testing
- NKTR-102, Eribulin, Ixabepilone
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
Lung Cancer
Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy may be more effective in preventing brain metastases.
- Trial name
- NCT00006344
- Testing
- radiation therapy
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Brain Metastases, Leptomeningeal Metastasis
GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
This study will test the safety of the study drug, GDC-0084, in combination with radiation therapy in people who have solid tumor brain metastases or leptomeningeal metastases.
- Trial name
- NCT04192981
- Testing
- GDC-0084, whole brain radiation therapy radiation
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Metastases
18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases
The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth.
- Trial name
- NCT02037945
- Testing
- 18F-FCH PET Scan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Malignant Neoplasm in the Brain
Stereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases
This randomized phase III trial studies stereotactic radiosurgery to see how well it works compared to clinical observation after surgery in treating patients with brain metastases.
- Trial name
- NCT00950001
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Metastatic Cancer
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
The aim of this study is to explore the efficacy and toxicity of icotinib combined with WBRT in treating patients with multiple brain metastases from NSCLC.
- Trial name
- NCT01514877
- Testing
- Icotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in patients with cancer that has spread from the primary site…
- Conditions
- Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
- Trial name
- NCT02360215
- Testing
- Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
- Where
- 220 sites in United States, Canada
- Volunteers
- 518 people
- Sponsor
- NRG Oncology
Brain Neoplasm, Brain Cancer
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
Brain tumors represent the most common solid tumor of childhood. Treatment generally entails surgery and radiation, but local recurrence is frequent.
- Conditions
- Brain Neoplasm, Brain Cancer, Brain Tumor, Primary
- Trial name
- NCT00001574
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Brain Metastases, Glioma of Brain
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised.
- Conditions
- Brain Metastases, Glioma of Brain, Brain Tumor, Metastatic Melanoma
- Trial name
- NCT03698162
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Bevacizumab Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
NSCLC Stage IV, Brain Metastases, Adult
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease…
- Trial name
- NCT06401824
- Testing
- Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
- Where
- 3 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Maastricht University Medical Center
Prophylactic Cranial Irradiation, Cumulative Incidence of Brain Metastases
Prophylactic Cranial Irradiation Versus Observation in Stage IV NSCLC Randomized Controlled Clinical Study
Lung cancer has remained the leading cause of cancer-related deaths worldwide. An important and frequent cause of morbidity in this patient group is the development of brain metastases (BM).
- Trial name
- NCT06014450
- Testing
- Prophylactic Cranial Irradiation for experiment arm
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Guizhou Medical University
Male Breast Cancer, Stage IV Breast Cancer
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
This phase I trial is studying the side effects and best dose of cediranib maleate when given together with whole brain radiation therapy in treating patients with brain metastases from non-small cell lung cancer.
- Conditions
- Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00937482
- Testing
- cediranib maleate, whole-brain radiation therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Brain Metastases
Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from…
- Trial name
- NCT00362817
- Testing
- carboplatin, temozolomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non Small Cell Lung Cancer, Brain Metastasis
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer
- Trial name
- NCT01891708
- Testing
- bevacizumab, standard chemotherapy and radiation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Li Liu
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled.
- Conditions
- Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
- Trial name
- BRIDGET (NCT05323955)
- Testing
- Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carey Anders, M.D.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.